七月 2026
- Home
- LifeMine
七月 2026的LifeMine市场份额分析
LifeMine is a clinical-stage biopharmaceutical company pioneering a bold new approach, Top-Down Drug DiscoveryTM, which leverages evolutionary insights from fungi to unearth next-generation precision medicines.
LifeMine(包含公司地区分支机构)
查看更多网站流量和参与度信息- lifeminetx.com
LifeMine收入截至 七月 2026为 25M - 50M
LifeMine主要域名产生的收入
3 年中LifeMine主要域名的收入
LifeMine主要域名的收入
LifeMine热门域名的总访问量
了解LifeMine市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
LifeMine热门域名的平均访问时长
分析LifeMine参与度指标。
过去 3 个月的平均访问时长
子公司明细
LifeMine热门域名的平均页面浏览量
了解LifeMine如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
LifeMine 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻LifeMine Therapeutics, Inc. received financing of $75M in Series D on Aug 26th '26.LifeMine Therapeutics announced $75 million in Series D and $188 million in Series E financing, totaling $263 million, to accelerate the clinical development of the company's lead program, LIFE-001, and advance its pipeline of transplantation and immunology therapies. LIFE-001 is a calcineurin activation inhibitor (CNai) delivered as a long-acting injectable and designed de novo to avoid the immunophilin-dependent organ damage associated with legacy calcineurin inhibitors (CNIs), such as cyclosporine, voclosporin, and tacrolimus.
八月 26, 2026阅读更多
新闻Lifeminetx hired Lata Jayaraman as chief medical officer and executive vice president of translational science on Dec 6th '22.LifeMine Therapeutics Inc., a biopharmaceutical company refashioning drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, today announced the appointment of Elliot Ehrich, M.D., as chief medical officer and executive vice president of translational science, and of Lata Jayaraman, Ph.D., as executive vice president and head of biology.
十二月 5, 2022阅读更多
查看 LifeMine 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
